Author: admin

  • Stocks Find Footing as Traders Track Bond Rout: Markets Wrap

    Stocks Find Footing as Traders Track Bond Rout: Markets Wrap

    (Bloomberg) — Stocks chalked up a modest rebound as traders tracked the selloff in long-dated bonds, fueled by anxiety over inflation and mounting government debt. Gold hit a fresh all-time high.

    European stocks rose 0.3% after suffering their steepest loss in a month in the previous session. Nasdaq 100 futures advanced 0.5% as Alphabet Inc. rallied in extended trading on Tuesday, buoyed by a ruling that Google won’t be forced to sell its Chrome browser. Contracts on the S&P 500 climbed 0.3% after two days of losses.

    While equities found firmer footing, the bond selloff deepened. The yield on 30-year Treasuries climbed three basis points, coming within a whisker of the 5% threshold. Japanese debt joined the rout, with 20-year yields hitting the highest since 1999. UK gilts weakened further, while euro-area bonds proved more resilient.

    The fragility of bonds underscores the strain from heavy public spending, which demands ever-rising bond issuance, and a broader erosion of confidence in sovereign credit. That uncertainty has spilled into equities, where traders are grappling with stretched valuations after a record rally, alongside persistent concerns over monetary policy and inflation.

    “I don’t see this movement as a threat to the rising trend of stock markets,” said Roland Kaloyan, head of equity strategy at Societe Generale SA. “We don’t see yields rising much further than their current levels. That being said, this bond selloff means that there will be an even greater focus on Friday’s US job data and their impact on the Fed’s easing policy.”

    Gold’s latest record comes as growing expectations for US interest-rate cuts bolster the metal’s attractiveness. The drop in bond and equities has also strengthened its appeal as a haven. Bullion climbed as much as 0.4% to hit 3,546.96 an ounce before paring gains.

    “President Trump’s continued efforts to erode the Fed’s policy independence are also shaking confidence, in turn helping hard assets such as gold,” wrote Michael Brown, senior research strategist at Pepperstone Group Ltd. “The bull case remains intact.”

    Corporate News:

    Alphabet Inc.’s Google will be required to share online search data with rivals while avoiding harsher penalties, including the forced sale of its Chrome business, a judge ruled in the biggest US antitrust case in almost three decades. Alphabet shares rose in after-hours trading. The US has revoked Taiwan Semiconductor Manufacturing Co.’s authorization to freely ship essential gear to its main Chinese chipmaking base, potentially curtailing its production capabilities at that older-generation facility. TSMC shares retreated in Taiwan. Apple Inc.’s lead artificial intelligence researcher for robotics has departed the company to join Meta Platforms Inc.’s competing effort, part of an exodus of AI talent from the iPhone maker. A group of Thames Water’s senior creditors has submitted a new operational plan to the UK regulator as part of its bid to rescue and take over the ailing utility. Hong Kong is probing allegations of insider dealing that involve at least two individuals at the stock exchange and the city’s financial regulator as well as brokers and social media influencers. Some of the main moves in markets:

    Stocks

    The Stoxx Europe 600 rose 0.3% as of 9:05 a.m. London time S&P 500 futures rose 0.3% Nasdaq 100 futures rose 0.5% Futures on the Dow Jones Industrial Average fell 0.1% The MSCI Asia Pacific Index fell 0.8% The MSCI Emerging Markets Index was little changed Currencies

    The Bloomberg Dollar Spot Index was little changed The euro was little changed at $1.1641 The Japanese yen fell 0.2% to 148.71 per dollar The offshore yuan was little changed at 7.1456 per dollar The British pound fell 0.1% to $1.3374 Cryptocurrencies

    Bitcoin fell 0.2% to $111,212.14 Ether was little changed at $4,318.2 Bonds

    The yield on 10-year Treasuries advanced three basis points to 4.29% Germany’s 10-year yield declined one basis point to 2.77% Britain’s 10-year yield advanced two basis points to 4.82% Commodities

    Brent crude fell 0.5% to $68.82 a barrel Spot gold rose 0.1% to $3,537.23 an ounce This story was produced with the assistance of Bloomberg Automation.

    ©2025 Bloomberg L.P.

    Continue Reading

  • Colon cancer doctor shares five life-saving lessons: Symptoms and risks you should know |

    Colon cancer doctor shares five life-saving lessons: Symptoms and risks you should know |

    Dr. Karen Zaghiyan, a prominent colorectal surgeon at Cedars-Sinai in Los Angeles, recently shared vital advice on bowel cancer in a widely viewed Instagram video. She offers straightforward guidance for anyone concerned about or diagnosed with colorectal cancer. Dr. Zaghiyan stresses the life-saving importance of early screening, particularly colonoscopies, and urges patients to seek second opinions to ensure accurate diagnoses. She warns against unverified remedies and emphasizes taking prompt, informed action when symptoms arise. Her advice highlights how timely medical decisions can dramatically improve outcomes, highlighting the critical role of awareness, professional consultation, and early intervention in combating colorectal cancer.

    5 hard truths about colon cancer

    1. Get a colonoscopy early

    Dr. Zaghiyan stresses that everyone should begin colorectal cancer screening at age 45, even if they feel healthy or have no family history. Colonoscopies allow doctors to visually inspect the entire colon and remove precancerous polyps before they develop into cancer. Unlike at-home stool tests, which can miss a significant number of polyps, colonoscopies are more than 95% effective at detecting and preventing colorectal cancer. Proper preparation, including dietary adjustments and the use of laxatives, is essential for an accurate examination. Patients should also plan for post-procedure transport due to sedation. Starting screenings early can dramatically increase the chances of detecting cancer at a curable stage.

    2. Take screening and diagnosis seriously

    Early detection is critical in improving survival rates for colorectal cancer patients. Dr. Zaghiyan notes that patients diagnosed at stage one have around a 90% chance of surviving at least five years, while those diagnosed at stage four have only a 10% five-year survival rate. Symptoms like rectal bleeding, changes in bowel habits, abdominal pain, fatigue, or unexplained weight loss should never be ignored. Delaying medical attention or dismissing these signs as minor issues can allow the disease to progress, making treatment far more complicated and reducing the likelihood of a positive outcome. Taking diagnosis and screening seriously can be the difference between life and death.

    3. Seek second opinions

    Dr. Zaghiyan strongly recommends getting a second opinion for any diagnosis or if symptoms are concerning. Misdiagnoses are not uncommon, and consulting multiple experts ensures that patients receive the most accurate assessment and treatment plan. For instance, rectal bleeding might be incorrectly attributed to hemorrhoids without proper examination. Patients should feel empowered to ask questions, challenge their care plans, and consult additional specialists if necessary. Taking the extra step to verify your diagnosis can prevent mistakes and provide access to the latest treatment options, potentially saving lives.

    4. Avoid unverified remedies

    Online advice and alternative treatments can be misleading or harmful. Dr. Zaghiyan warns against trusting unproven cures, such as extreme diets, supplements, or home remedies promoted online. Instead, patients should rely on evidence-based medical treatments and consult registered cancer dietitians to safely complement conventional therapy. For those seeking innovative approaches, enrolling in clinical trials with rigorous oversight is far safer than following anecdotal or unverified claims. Sticking to verified medical advice increases the likelihood of successful treatment and minimizes unnecessary risk.

    5. Act timely and follow medical guidance

    Delaying treatment is one of the most dangerous decisions a patient can make. Dr. Zaghiyan emphasizes that once concerning symptoms appear or a diagnosis is confirmed, timely action can mean the difference between curable and advanced disease. Following your doctor’s recommendations without unnecessary delay, adhering to medication schedules, and attending follow-up appointments is crucial. Patients should avoid waiting to “see if it goes away” and instead act promptly, as early intervention substantially increases survival chances.

    Symptoms and risks of colon cancer

    Colorectal cancer often develops silently, showing few or no symptoms in its early stages. Being aware of both warning signs and risk factors is crucial, as early detection can dramatically improve survival rates. Individuals should pay attention to changes in their digestive health and seek prompt medical evaluation if they notice unusual patterns or persistent discomfort.Common symptoms:

    • Blood in stool or rectal bleeding
    • Persistent changes in bowel habits (diarrhea, constipation, or narrowing stools)
    • Abdominal pain, cramping, or bloating
    • Fatigue and unexplained weight loss
    • Frequent or urgent bowel movements

    Risk factors:

    • Age over 45
    • Family history of colorectal cancer or polyps
    • Personal history of inflammatory bowel disease (ulcerative colitis or Crohn’s disease)
    • Obesity, smoking, or high consumption of processed foods
    • Sedentary lifestyle

    Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making any changes to your health routine or treatment.


    Continue Reading

  • Three powerful antibodies discovered with potential to treat mpox

    Three powerful antibodies discovered with potential to treat mpox

    Researchers at Mount Sinai have identified three antibodies that target mpox and prevent severe disease in vivo. The work positions A35-specific antibodies as candidates for therapeutic development.

    3D illustration of monkeypox virus particles under a microscope, showing oval-shaped virions with complex surface structure in a red background


    Researchers at the Icahn School of Medicine at Mount Sinai have identified three monoclonal antibodies against monkeypox (also commonly referred to as mpox) that block viral spread and protect against severe disease. The findings provide a potential basis for developing targeted therapies for orthopoxvirus infections.

    The findings, published in Cell, reveal that the antibodies – isolated from an individual previously infected with mpox – target a protein called A35. In laboratory studies, the antibodies not only halted viral spread but also shielded rodents from severe illness and prevented death entirely. Importantly, analysis of patient samples showed that people who had been infected with mpox naturally carry high levels of these antibodies and that their presence is linked to milder disease and fewer hospitalisations.

    A virus in urgent need of treatment

    Mpox has been a global health concern since a multi-country outbreak in 2022. The virus, a close relative of smallpox, is transmitted primarily through direct contact and causes rash, lymphadenopathy and fever. Although most cases resolve, infection can result in permanent scarring and, in severe instances, be life threatening.

    Despite repeated warnings from the World Health Organization, which has declared mpox a public health emergency of international concern twice since 2022, there is still no approved drug to treat the disease. Clinical trials of the most advanced candidate therapy have failed to demonstrate effectiveness, highlighting the urgent need for alternatives.

    monkeypox virus monkeypox virus

    Monkeypox is a zoonotic orthopoxvirus infection that causes fever, lymph node swelling and a distinctive pustular rash. After entering via the respiratory tract or skin, the virus spreads systemically and produces lesions across the body.
    Image credit: Corona Borealis Studio / Shutterstock

    That urgency is precisely what drove the Mount Sinai team.

    “A previous study published in 2023 by our team showed that human antibodies targeting the viral protein A35 were unusually increased in sera in response to mpox infection compared with vaccination for smallpox or antibodies against other viral proteins,” explained Dr Camila Coelho, Assistant Professor of Microbiology at Icahn Mount Sinai.

    Our team showed that human antibodies targeting the viral protein A35 were unusually increased in sera in response to mpox infection compared with vaccination for smallpox or antibodies against other viral proteins.

    “Based on this earlier finding, we hypothesised that antibodies targeting A35 from mpox-infected individuals would be highly protective against orthopoxviruses, since the viruses in this family share high genetic similarity. We aimed to address the urgent unmet need for effective treatments for orthopoxviruses, and with the help of our outstanding collaborators, I am very proud to say that we are close to achieving that goal.”

    What makes the discovery particularly compelling is the antibodies’ binding site. The researchers found that the antibodies latch onto a region of A35 that is highly conserved across not just orthopoxviruses – including mpox – but the entire poxvirus family. As this site is unlikely to mutate, the antibodies are less vulnerable to immune escape, making them robust drug candidates.

    “Ours is the first report of the crystal structure of a human antibody bound to an mpox virus protein, providing a detailed map of a vulnerability in the virus,” said Dr Raianna Fantin, postdoctoral researcher and first author of the study.

    “It is also the first time that monoclonal antibodies against orthopoxviruses were quantified in human sera. We were surprised by how consistently people recovering from mpox infection produced antibodies targeting the same A35 epitope of the virus as the antibodies we discovered.”

    Next steps towards therapy

    The Icahn School of Medicine has already patented the antibodies, signalling confidence in their potential clinical use. However, the team is clear that the work is still in its early stages. The antibodies must undergo rigorous preclinical safety checks and eventually human clinical trials before becoming available as a therapy.

    For now, the researchers are focusing on two tracks: advancing the antibodies through further testing and leveraging their insights into the immune response to guide future strategies. Their dual approach could yield not only a treatment for mpox but also a foundation for tackling related viruses.

    The discovery comes at a critical time. Mpox cases continue to be reported globally and no approved treatments are available. The identification of targeted antibodies offers a potential path toward effective therapy.

    Continue Reading

  • Emily Atack, star of ‘The Inbetweeners’, opens up about sexual assault on sets

    Emily Atack, star of ‘The Inbetweeners’, opens up about sexual assault on sets

    Emily Atack, the star of ‘The Inbetweeners’ and ‘Rivals’, has shared that she has faced sexual assault during her career.

    Speaking to the ‘Radio Times’, the 35-year-old actress revealed, “I’ve been sexually assaulted at work throughout my career, whether it’s on the actual set, or at a wrap party.”

    Advertisement

    Atack, who previously presented the 2023 documentary ‘Emily Atack: Asking For It?’ about online sexual harassment, explained that she has personally experienced harassment in the digital space as well.

    In the programme, she revealed receiving hundreds of explicit messages and pictures every day, and explored why some men target women online and what could be done to stop this behaviour.

    Because of her unpleasant experiences, Atack welcomed the growing use of intimacy coordinators on film and TV sets. These professionals oversee scenes involving sexual content to ensure actors feel safe and supported.

    Also Read: Cardi B wins $24M nail attack case in court against security guard

    “It shows that people are listening and that there has to be a shift in behaviour on sets,” she said. She added, “They are there for support if you feel uncomfortable… Whether you’re a man or a woman,” and acknowledged that she hasn’t always felt safe in her career.

    Beyond her professional life, Atack is also focused on being a thoughtful parent. She wants to raise her young son, Barney, with a strong understanding of respect and self-worth.

    “I want him to know how to treat women and know his own worth. So he doesn’t feel he has to follow awful men online that are preying on vulnerable boys,” she told the ‘Radio Times’.

    Atack described her family as “very open.” She said, “I want Barney to know he can talk to me about anything. That’s the mother I want to be.”

    Atack’s experiences with harassment are not new. She was 17 when she was cast as Charlotte Hinchcliffe in the popular Channel 4 coming-of-age comedy ‘The Inbetweeners’. In interviews, she has shared that she began receiving unwanted attention from men from a very young age.


    Continue Reading

  • 5 weekend tasks for healthy eating all week

    5 weekend tasks for healthy eating all week

    It isn’t easy to prepare home-cooked, healthy meals all week long. But your chances of success are much higher if you’re not starting from scratch every night. Realizing this, dedicate a small chunk of your weekend to getting a jump on healthy cooking for the week.

    Tackle one or two easy, time-consuming cooking tasks while you binge-watch your favorite TV shows. Or simply roast a chicken while you work in your garden or read a novel. Your Thursday self will thank you.

    Guarantee healthy weekday meals with some Sunday slicing and simmering.

    1. Chop vegetables: Dice the onions, peppers and celery you’ll need this week. This simple task saves a lot of time during the dinner rush.
    2. Cook grains or lentils: Brown rice and dried lentils take 30 to 45 minutes to cook. Let them simmer while you watch a movie on Sunday.
    3. Make a sauce: A flavor-packed sauce in your fridge is like money in the bank. Withdraw it on a busy night for a quick, flavorful meal. Salad dressing, too! You’re likely to eat more salad with ready-made ranch.
    4. Roast one vegetable: Try butternut squash, carrots, parsnips, cauliflower or beets. Add roasted vegetables to salads and grain bowls all week.
    5. Cook one protein: If you cook salmon on Sunday, you’re halfway to salmon cakes or salmon Nicoise salad. A Sunday roast is never a bad idea, either. Add leftovers to tacos and salads.

    Created by the executive wellness chef and registered dietitians at the Mayo Clinic Healthy Living Program.

    Relevant reading

    Cook Smart, Eat Well

    Healthy, flavorful meals are well within reach for anyone. This book is full of recipes that are easy to put together quickly with basic cooking techniques. Delicious kid friendly recipes, healthy desserts, snacks and side dishes. Being successful in the kitchen doesn’t mean you need to be a gourmet chef. Learn standard food preparation methods and cooking techniques for preparing a wide variety of tasty and healthy meals.

    Discover more Nutrition & Fitness content from articles, podcasts, to videos.

    View Nutrition & Fitness

    Continue Reading

  • Shell scraps construction of biofuels plant in Rotterdam | Shell

    Shell scraps construction of biofuels plant in Rotterdam | Shell

    Shell has axed the construction of its biofuels plant in the Netherlands, ending what would have been one of the biggest converters of waste into green jet fuel in Europe.

    The oil company, which paused construction at the site in July last year to tackle technical problems, said it had decided not to restart building after it found the plant would be “insufficiently competitive” to meet demand for “affordable, low-carbon products”.

    The move to scrap the project in Rotterdam marks another setback for its biofuel designs, after the company cancelled a sustainable aviation fuel (SAF) project on Singapore’s Bukom Island in March 2023.

    It comes amid a wider shift away from renewable energy projects in the oil and gas sector as fossil fuel companies pursue higher profits.

    In March last year Shell watered down a key emissions target, setting out a plan to reduce the carbon emissions intensity of the energy it sells by 15-20% by the end of the decade compared with its previous goal of 20%.

    Shell began construction of the plant in Rotterdam in the Netherlands in 2021, initially expecting to start producing up to 820,000 tonnes of biofuels, with plans to bring it online in April 2024. This was later pushed back to 2025.

    Machteld de Haan, the company’s head of downstream, renewables and energy solutions, said: “As we evaluated market dynamics and the cost of completion, it became clear that the project would be insufficiently competitive to meet our customers’ need for affordable, low-carbon products.

    “This was a difficult decision, but the right one, as we prioritise our capital towards those projects that deliver both the needs of our customers and value for our shareholders.”

    She added that the company continued “to believe that low-carbon molecules, including biofuels, will underpin the future energy system” and that Shell was “one of the world’s largest traders and suppliers of biofuels, including sustainable aviation fuel”.

    skip past newsletter promotion

    About half of the biofuels from the plant in Rotterdam were expected to be used for SAF, made from waste cooking oil and animal fat.

    Proponents for SAF believe it could be crucial for airlines to cut their carbon emissions in line with global climate targets, although critics argue it is not a realistic alternative given the limited timescale to prevent rising emissions from creating a climate disaster. The aviation industry accounts for about 3% of the world’s carbon emissions, according to the International Energy Agency.

    Continue Reading

  • EU SME Centre 2025/2026 Survey

    EU SME Centre 2025/2026 Survey

    European SMEs in China face growing challenges from regulatory complexity, competition, and financial constraints, with smaller firms particularly affected. The upcoming 2025/2026 Position Paper is expected to outline recommendations to improve financing, regulatory clarity, payment practices, IP protection, and fair market access.


    European small and medium-sized enterprises (SMEs) continue to play a significant role in China’s economy, contributing to trade, innovation, and local employment. However, operating in the Chinese market has become increasingly complex, as companies contend with regulatory uncertainty, competitive pressures, and financial constraints. Understanding the evolving landscape is critical for SMEs seeking to sustain and expand their presence in China.

    The EU SME Centre, in collaboration with the European Union Chamber of Commerce in China, conducted a survey between March and May 2025 to gather insights directly from European SMEs. While the final position paper has not yet been released, the preliminary findings of the survey suggest several emerging trends and concerns that are likely to shape the final recommendations —and these insights form the basis of our current article.  The survey captures the experiences of businesses operating across a range of sectors, including machinery, professional services, automotive and auto components, chemicals and petroleum, and medical devices, and provides a comprehensive view of the challenges, opportunities, and strategic priorities for SMEs in the country.

    Find Business Support

    Survey findings highlight the geographic concentration of European SMEs, with a significant presence in Shanghai, Beijing, Nanjing, and Guangzhou, while smaller clusters operate in other commercial hubs such as Tianjin, Shenzhen, Shenyang, Chengdu, and Chongqing. This concentration reflects SMEs’ preference for established economic centers with robust infrastructure and business networks, while also pointing to potential growth opportunities in second-tier cities where competition may be less intense but local market knowledge and strategic planning remain essential.

    This article draws on the survey data and broader policy developments to provide a forward-looking analysis of the challenges European SMEs face in China, as well as the measures and strategies that can help them navigate the market effectively. Following up on the 2024/2025 Position Paper, the article also previews the key recommendations expected in the 2025/2026 Position Paper, which will outline actionable steps to support SMEs, enhance competitiveness, and foster a more transparent and equitable business environment.

    Explore vital economic, geographic, and regulatory insights for business investors, managers, or expats to navigate China’s business landscape. Our Online Business Guides offer explainer articles, news, useful tools, and videos from on-the-ground advisors who contribute to the Doing Business in China knowledge.
    Start exploring

    Challenges facing European SMEs in China: Local competition remain the top concern

    European SMEs operating in China encounter a complex set of challenges that affect their growth, operations, and strategic planning. Competition with Chinese private companies remains the most pressing concern, compounded by slower economic growth and rising operational costs. Smaller firms are particularly exposed to cashflow pressures, often intensified by late payments, which can limit investment and responsiveness. Larger European companies, while also facing competition, prioritize talent management and navigating regulatory complexity, reflecting differing resources and operational priorities.

    Access to financing continues to constrain SMEs. Many struggle to obtain loans from local banks and have limited access to government incentives or cross-border funding, forcing careful capital management. By contrast, larger firms generally face fewer constraints, highlighting the disparities in scale and institutional access. Revenue sources further underscore these differences: SMEs often rely heavily on European clients, following larger partners into China, while larger firms are more integrated with domestic clients.

    Find Business Support

    Regulatory and administrative hurdles remain a persistent challenge. SMEs report difficulties in understanding opaque requirements, securing licenses and permits, and navigating lengthy or inconsistent registration processes. Inconsistent enforcement across jurisdictions adds further uncertainty, increasing operational risk. Larger companies face similar issues on a broader scale, but SMEs are disproportionately affected due to limited resources. Late payments and unfavorable contract terms, particularly from private companies, create additional liquidity pressures.

    These delays require SMEs to dedicate time and resources to debt management, which can affect day-to-day operations and strategic initiatives.

    Intellectual property protection, while improving, continues to pose difficulties. High costs, piracy, counterfeiting, and limited enforcement capacity disproportionately impact SMEs, particularly in sectors where patents and proprietary technology are critical. Larger companies are better equipped to manage these risks, highlighting the resource gap between SMEs and major firms.

    Anticipated recommendations for European SMEs in China

    The 2025/2026 Inter-Chamber SME Working Group Position Paper, due in September 2025, is expected to provide a forward-looking roadmap to support European SMEs navigating China’s complex business landscape.

    Drawing on insights from recent consultations and surveys, the forthcoming publication will likely emphasize measures to strengthen financial access, regulatory clarity, operational resilience, and competitiveness.

    Enhancing financial accessibility

    Securing affordable and reliable financing remains a critical hurdle for smaller European companies in China. The Position Paper is expected to call for targeted programs that facilitate SME lending, streamline access to government incentives, and improve cross-border funding mechanisms. Such initiatives would help companies maintain liquidity, fund growth, and invest in innovation.

    Simplifying regulatory and administrative processes

    European SMEs often face cumbersome administrative requirements and opaque regulations. Recommendations are likely to focus on improving transparency, reducing duplication in licensing and approval procedures, and fostering consistent enforcement across regions. By clarifying regulatory expectations, SMEs could better plan operations and navigate compliance with greater confidence.

    Supporting cashflow and payment practices

    Unpredictable payment terms and delays can strain SME operations. The upcoming Position Paper may advocate for frameworks that encourage fair payment practices and promote timely settlements, particularly in business-to-business transactions, ensuring SMEs can allocate resources efficiently and reduce financial risk.

    Strengthening IPR

    Protecting proprietary technology and brand assets remains essential for SMEs, particularly in innovation-driven sectors. Recommendations are expected to highlight measures that simplify IP registration, enhance enforcement mechanisms, and support companies in addressing counterfeiting and infringement, helping to secure competitive advantage in China’s dynamic market.

    Fostering a level playing field and talent access

    The Position Paper is likely to underline the importance of creating fair opportunities for SMEs alongside domestic competitors, including access to procurement, financing, and talent. Policies that facilitate workforce mobility, provide supportive infrastructure, and encourage skills development will be crucial for sustaining innovation and operational excellence.

    Is China still a worthy market for EU SMEs?

    Short answer is: Yes — but only for those that know where they belong. Amid mounting challenges, ranging from regulatory complexities and economic slowdown to fierce competition from domestic players, China is no longer a catch-all growth engine for European SMEs—it demands a more nuanced and strategy-driven approach. Rewards will go to companies that play to their strengths, adapt to local realities, and treat China as one part of a wider Asian strategy.

    Few drivers of China’s attractiveness for EU SMEs:

    • Market size and growth: As the world’s second-largest economy and second-largest healthcare and consumer market, China still expands faster than most advanced economies, even in a slower-growth era.
    • Demand for quality: Chinese buyers are moving up the value chain, seeking premium, sustainable, and niche products. This is where EU SMEs excel, from precision machinery and specialty food and beverage to medtech and green solutions.
    • Policy push for upgrading: Strategic sectors such as biotech, renewable energy, and advanced manufacturing continue to receive heavy government support, aligning well with European expertise.
    • Digital sales channels: Cross-border e-commerce platforms like Tmall Global and JD Worldwide lower entry barriers, allowing SMEs to test the market without committing to full-scale operations.
    • Supply chain and RCEP access: China’s role in regional supply chains and its participation in the Regional Comprehensive Economic Partnership (RCEP) enhance connectivity and trade facilitation across Asia, offering EU SMEs broader access through a China base.

    Again, China no longer offers a one-size-fits-all solution. The path to success for EU SMEs lies in specializing in high-value or niche sectors, where distinct European expertise can differentiate offerings and mitigate the pressure of mass-market competition.

    Localized partner and distributor networks are critical to navigating regulatory hurdles and sustaining market momentum. Additionally, digital-first entry routes, such as cross-border e-commerce and localized online sales platforms, offer a scalable, lower-risk approach to market entry.

    In sum, China remains a valuable destination for EU SMEs, but only if approached strategically. Companies that align with niche markets, build the right partnerships, leverage digital routes, and integrate China into a broader Asian or global strategy are likelier to thrive. This isn’t about writing off the market, it’s about recognizing how it must be approached differently today.

    About Us

    China Briefing is one of five regional Asia Briefing publications, supported by Dezan Shira & Associates. For a complimentary subscription to China Briefing’s content products, please click here.

    Dezan Shira & Associates assists foreign investors into China and has done so since 1992 through offices in Beijing, Tianjin, Dalian, Qingdao, Shanghai, Hangzhou, Ningbo, Suzhou, Guangzhou, Haikou, Zhongshan, Shenzhen, and Hong Kong. We also have offices in Vietnam, Indonesia, Singapore, United States, Germany, Italy, India, and Dubai (UAE) and partner firms assisting foreign investors in The Philippines, Malaysia, Thailand, Bangladesh, and Australia. For assistance in China, please contact the firm at china@dezshira.com or visit our website at www.dezshira.com.

     

    Continue Reading

  • Ooni’s newest pizza oven adds AI to your slice

    Ooni’s newest pizza oven adds AI to your slice

    Have you ever looked at your pizza oven and wished it was just a little bit smarter? Ooni has, and so its new Volt 2 comes loaded with “Pizza Intelligence,” an adaptive heating system designed to deliver a more even and consistent cooking temperature.

    The Volt 2 is an indoor oven, able to cook pizzas up to 13 inches in diameter, but it’s still small enough to fit on a countertop — though we’ve found other indoor pizza ovens too smoky to really use inside. Pizza Intelligence is new to the Volt 2 and uses sensor data to adjust the top and bottom heating elements, “minimizing temperature fluctuations and cold spots.” It’s a little less exciting than the name suggests.

    The Volt 2 has a max temperature of 450 Celsisus (842F), right in the recommended range for cooking traditional Neapolitan pizza, which Ooni says should take about 90 seconds. That’s one of the three presets, with New York and deep-pan pizza, too, and the oven “adjusts temperature and crisping intensity” to suit each style. You can also add programmable custom presets if you prefer a different type of pie.

    The Volt 2 will be available from October 1st for £499 (about $670). We’ll update this with US pricing when we have it.

    Continue Reading

  • Rescuers race to find Afghan quake survivors as death toll rises | Earthquakes News

    Rescuers race to find Afghan quake survivors as death toll rises | Earthquakes News

    The United Nations has warned of an exponential rise in casualties from a powerful earthquake in eastern Afghanistan, as the Taliban said the death toll had surpassed 1,400 on Tuesday, with more than 3,000 people injured.

    The figures provided by Taliban government spokesman Zabihullah Mujahid were mainly for the province of Kunar.

    Sunday night’s magnitude 6 earthquake affected several provinces, causing extensive damage. It flattened villages and trapped people under the rubble of homes constructed mainly of mud bricks and wood, which were unable to withstand the shock.

    Rough terrain is hampering rescue and relief efforts, forcing Taliban authorities to airdrop dozens of commandos to evacuate the injured from places where helicopters cannot land.

    A magnitude 5.2 aftershock, close to the epicentre of Sunday’s earthquake, rattled the area on Tuesday, according to the United States Geological Survey. There were no immediate reports of damage.

    Indrika Ratwatte, the United Nations resident coordinator for Afghanistan, said rescuers are scrambling in a “race against time” to reach the mountainous and remote area. In a media briefing in Geneva on Tuesday, he warned of a surge in casualty numbers.

    “We cannot afford to forget the people of Afghanistan who are facing multiple crises, multiple shocks, and the resilience of the communities has been saturated,” Ratwatte said, urging the international community to step forward.

    “These are life-and-death decisions while we race against time to reach people,” he said.

    It is the third strong earthquake since the Taliban seized power in 2021, and the latest crisis to beset Afghanistan, which is reeling from deep cuts to aid funding, a weak economy, and millions of Afghans forcibly returned from Iran and Pakistan.

    The Taliban government has appealed for assistance from the international community and the humanitarian sector. However, help for the country is in short supply due to competing global crises and reduced aid budgets in donor countries.

    Continue Reading

  • Hidden viruses in our DNA could be medicine’s next big breakthrough

    Hidden viruses in our DNA could be medicine’s next big breakthrough

    You are mostly but not entirely human. If we crunch the numbers, 8 percent of your genome actually comes from viruses that got stranded there. This viral detritus is a souvenir from our evolutionary past, a reminder that viruses have been with us from the very beginning.

    Usually, this 8 percent of your DNA — the viral bits — are kept silent. Scientists call it part of the “dark matter” in your genome.

    Now scientists at La Jolla Institute for Immunology (LJI) have published a first look at a key viral protein. In a study published in Science Advances, LJI researchers revealed the first three-dimensional structure of a protein from one of these ancient “human endogenous retroviruses (HERVs).”

    The team mapped the surface envelope glycoprotein (Env), the antibody target of the most active HERV, marking a milestone in structural biology. “This is the first human HERV protein structure ever solved — and only the third retroviral envelope structure solved overall, after human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV),” says Erica Ollmann Saphire, Ph.D., MBA, LJI President, CEO, and Professor.

    This discovery opens the door to new strategies for diagnosing and treating disease. Back in the evolutionary past, HERV-K Env proteins studded the outside of the HERV-K retroviruses. But in modern humans, HERV-K Env proteins show up on the surface of certain tumor cells and in patients with autoimmune and neurodegenerative diseases, making them a valuable target for developing novel diagnostics and therapies.

    “In many disease states, like autoimmune diseases and cancer, these genes re-awaken and start making pieces of these viruses,” says Saphire. “Understanding the HERV-K Env structure, and the antibodies we now have, opens up diagnostic and treatment opportunities.”

    An unexpected “twist”

    Until now, HERV proteins had been invisible. They’ve proven too mobile — and too twitchy — to be seen with even the most sophisticated imaging techniques. Solving the structure of HERV-K Env was especially challenging because the LJI team needed to capture the protein’s delicate “pre-fusion” state.

    Envelope proteins are full of potential energy — they’re essentially spring-loaded to merge with a host cell to start the infection process. This means pre-fusion proteins are prone to spontaneous switching to their later, post-fusion state. “You can look at them funny, and they’ll unfold,” says LJI Postdoctoral Fellow Jeremy Shek, who spearheaded the study as co-first author with LJI Postdoctoral Fellow Chen Sun, Ph.D.

    To study the three-dimensional structure of HERV-K Env, the researchers introduced small substitutions to lock the protein’s structure in place, while preserving its natural shape. Saphire and her team have used this approach before to reveal the structures of key proteins on Ebola virus, Lassa virus, and more. The researchers also discovered and characterized specific antibodies that helped anchor different versions of the viral proteins.

    After stabilizing their HERV-K Env structures, the LJI team used a high-resolution imaging technique called cryo-electron microscopy to capture 3D images of HERV-K Env at three key moments: cell surface, in the act of driving infection, and when it locks together with antibodies.

    Many viral envelope glycoproteins have a trimer structure, but HERV-K Env is different from anything scientists had seen before, including trimers from other retroviruses. Unlike the shorter, squatter trimers made by HIV and SIV, the HERV-K Env is tall and lean. Further, the protein’s fold — the weaving together of strands and coils that build the working machine — is unlike any other retrovirus.

    A new path for clinical research

    The new LJI study opens the door to using HERV-K Env to our advantage. Understanding the HERV-K Env structure, and how antibodies target it, may prove useful for developing diagnostic tools or new therapeutics.

    For example, many types of cancer cells — from breast cancers to ovarian cancers — but not healthy cells, are dotted with HERV-K Env proteins. This means antibodies against HERV could distinguish cancer cells from healthy cells. As Sun explains, scientists could develop cancer immunotherapies that zero in on HERV-K Env to track down tumor cells. “We can use it as a strategy to specifically target cancer cells,” says Sun.

    People with autoimmune diseases such as lupus or rheumatoid arthritis also express HERV-K Env on their cells. Some scientists suspect that patients’ immune cells see these strange proteins and think the body is under attack. Just like during a normal viral infection, their B cells start making antibodies against HERV-K Env proteins.

    “Understanding how antibodies recognize these proteins was challenging because there was no structure and precious few good antibodies yet available,” says Saphire.

    So the LJI team made their own panel of antibodies to reveal how the immune system can target the different subunits of the molecule in all its different shapes. Once scientists understand how these antibody attacks work, they can try to intervene and stop harmful inflammation.

    The scientists also tested the idea that their antibodies may also be useful tools for diagnosing many autoimmune diseases. They used the antibodies to try and hunt down immune cells in samples from patients with rheumatoid arthritis and lupus. When Saphire and her colleagues tagged these antibodies with a molecular flag, they were able to quickly detect HERV-K Env on neutrophils, a type of immune cell that can cause inflammation.

    “These antibodies marked aberrant HERV display on neutrophils from rheumatoid arthritis and lupus patients, but not healthy controls,” says Saphire.

    The interest in HERVs is quickly growing, and scientists are finding more and more diseases where HERV-K Env crops up. “We can really pick whatever disease we’re interested in and go down that route,” says Shek.

    These projects may someday advance clinical care — and our fundamental understanding of human biology. After all, we’re all part virus. It’s time to get to know that part of ourselves.

    Additional authors of the study, “Human endogenous retrovirus K (HERV-K) envelope structures in pre- and postfusion by cryo-EM,” were Elise M. Wilson, Fatemeh Moadab, Kathryn M. Hastie, Roshan R. Rajamanickam, Patrick J. Penalosa, Stephanie S. Harkins, Diptiben Parekh, Chitra Hariharan, Dawid S. Zyla, Cassandra Yu, Kelly C.L. Shaffer, Victoria I. Lewis, Ruben Diaz Avalos, and Tomas Mustelin,

    This study was supported by a Curebound Discovery Grant (13502-01-000-408) and by LJI & Kyowa Kirin, Inc. (KKNA-Kyowa Kirin North America; and a Kirin North America Accelerator Grant [18030-01-000-408]).

    Continue Reading